-
SynerK Announces SNK-2726 Advances with First Subject Dosed in Phase I Clinical Trial
SynerK announced today that its leading asset , SNK-2726, developed using the GalNexus platform, has been successfully dosed to the first subject in a Phase I clinical trial in China. This follows the receipt of Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) and United States Food and Drug Administration (US FDA).
넶0 2025-05-14 -
施能康siRNA药物SNK-2726临床试验申请获美国FDA批准！
2025年2月27日，施能康公司（Synerk）宣布，公司自主研发的靶向血管紧张素原（AGT）的寡核苷酸（siRNA）候选药物SNK-2726已获得美国食品药品监督管理局（FDA）临床试验申请（IND）批准。
넶120 2025-02-28 -
Huadong Medicine Co., Ltd. and SynerK reached a strategic cooperation to jointly develop a novel siRNA drug SNK-2726
December 27, 2024 - Hangzhou Sino-US Huadong Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine"), a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963), and SynerK PharmaTech (Suzhou) Co., Ltd. (hereinafter referred to as "SynerK") have reached a strategic cooperation. The two parties will jointly develop the small nucleic acid (siRNA) drug SNK-2726, targeting angiotensinogen (AGT) for the treatment of hypertension.
넶367 2024-12-30 -
喜报|施能康入选“姑苏重大创新团队”
喜报！在2024年（第十六届）苏州国际精英创业周暨第五届“苏州科学家日”开幕式现场，施能康医药科技（苏州）有限公司的兰涛、蒋伟文、郁东博士团队被授予“姑苏重大创新团队“称号。
넶512 2024-07-11
